Related Experiment Video
Updated: Jun 21, 2026
10:41
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Thwarting dyskinesia by targeting mTORC1.
1Center for Neural Science, New York University, New York, NY 10003, USA. eklann@cns.nyu.edu
Science Signaling
|July 23, 2009
Summary
New Parkinson's disease research reveals l-DOPA activates mTOR signaling, causing dyskinesia. Blocking mTORC1 may prevent this side effect without reducing l-DOPA's benefits.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder.
- l-DOPA is a primary treatment for PD symptoms.
- l-DOPA can induce involuntary movements known as dyskinesia.
Purpose of the Study:
- To investigate the molecular mechanisms underlying l-DOPA-induced dyskinesia.
- To explore the role of the protein kinase mTOR (mammalian target of rapamycin) in PD.
- To determine if targeting mTOR signaling could mitigate l-DOPA side effects.
Main Methods:
- Utilized a mouse model of Parkinson's disease.
- Administered l-DOPA and assessed motor symptoms and neuronal activity.
- Investigated the activation status of mTOR and its specific complex, mTORC1.
- Examined the effects of blocking mTORC1 signaling on l-DOPA efficacy and dyskinesia.
Main Results:
- l-DOPA treatment led to persistent activation of mTOR in specific neurons in the striatum.
- Blocking mTORC1 signaling effectively prevented the development of l-DOPA-induced dyskinesia.
- Inhibition of mTORC1 did not interfere with the beneficial anti-Parkinsonian effects of l-DOPA.
Conclusions:
- Persistent mTORC1 activation in striatal medium spiny neurons is implicated in l-DOPA-induced dyskinesia.
- mTORC1 represents a promising therapeutic target for managing dyskinesia in Parkinson's disease patients.
- Selective blockade of mTORC1 could offer a strategy to improve l-DOPA therapy outcomes.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...